Iovance Shares Fall After Sales of Cancer Drug Miss Estimate

Dow Jones2025-03-01

By Katherine Hamilton

Iovance Biotherapeutics shares declined after its primary cancer treatment fell short of revenue expectations.

The stock fell 19% to $4.28 on Friday, at one point dropping to a 52-week low of $3.62. Shares are down 75% in the past year.

The San Carlos, Calif., biotechnology company said Thursday revenue from Amtagvi was $48.7 million in the fourth quarter, missing Wall Street's estimate of $54 million. Full-year revenue for the product of $103.6 million also fell short of the $109 million analyst forecast.

The February 2024 launch of Amtagvi, which treats patients with metastatic melanoma, was the primary driver of revenue growth during the year, Iovance said.

Revenue overall rose to $73.7 million, up from $482 million the year before. Analysts polled by FactSet expected revenue of $72.1 million.

Iovance posted a loss of $78.6 million, or 26 cents a share, compared with a loss of $116.4 million, or 45 cents a share, in the prior year. Analysts expected a loss of 27 cents a share, according to FactSet.

Iovance reaffirmed its total product revenue guidance of $450 million to $475 million for this year. Analysts were guiding for $445.5 million.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

February 28, 2025 15:22 ET (20:22 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2516306243?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-01 04:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2516306243","market":"sh","top_or_hot":-1,"title":"Iovance Shares Fall After Sales of Cancer Drug Miss Estimate","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<p>\n  Iovance Biotherapeutics shares declined after its primary cancer treatment fell short of revenue expectations. \n</p>\n<p>\n  The stock fell 19% to $4.28 on Friday, at one point dropping to a 52-week low of $3.62. Shares are down 75% in the past year. \n</p>\n<p>\n  The San Carlos, Calif., biotechnology company said Thursday revenue from Amtagvi was $48.7 million in the fourth quarter, missing Wall Street's estimate of $54 million. Full-year revenue for the product of $103.6 million also fell short of the $109 million analyst forecast. \n</p>\n<p>\n  The February 2024 launch of Amtagvi, which treats patients with metastatic melanoma, was the primary driver of revenue growth during the year, Iovance said. \n</p>\n<p>\n  Revenue overall rose to $73.7 million, up from $482 million the year before. Analysts polled by FactSet expected revenue of $72.1 million. \n</p>\n<p>\n  Iovance posted a loss of $78.6 million, or 26 cents a share, compared with a loss of $116.4 million, or 45 cents a share, in the prior year. Analysts expected a loss of 27 cents a share, according to FactSet. \n</p>\n<p>\n  Iovance reaffirmed its total product revenue guidance of $450 million to $475 million for this year. Analysts were guiding for $445.5 million. \n</p>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 28, 2025 15:22 ET (20:22 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Iovance Shares Fall After Sales of Cancer Drug Miss Estimate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIovance Shares Fall After Sales of Cancer Drug Miss Estimate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-01 04:22</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<p>\n  Iovance Biotherapeutics shares declined after its primary cancer treatment fell short of revenue expectations. \n</p>\n<p>\n  The stock fell 19% to $4.28 on Friday, at one point dropping to a 52-week low of $3.62. Shares are down 75% in the past year. \n</p>\n<p>\n  The San Carlos, Calif., biotechnology company said Thursday revenue from Amtagvi was $48.7 million in the fourth quarter, missing Wall Street's estimate of $54 million. Full-year revenue for the product of $103.6 million also fell short of the $109 million analyst forecast. \n</p>\n<p>\n  The February 2024 launch of Amtagvi, which treats patients with metastatic melanoma, was the primary driver of revenue growth during the year, Iovance said. \n</p>\n<p>\n  Revenue overall rose to $73.7 million, up from $482 million the year before. Analysts polled by FactSet expected revenue of $72.1 million. \n</p>\n<p>\n  Iovance posted a loss of $78.6 million, or 26 cents a share, compared with a loss of $116.4 million, or 45 cents a share, in the prior year. Analysts expected a loss of 27 cents a share, according to FactSet. \n</p>\n<p>\n  Iovance reaffirmed its total product revenue guidance of $450 million to $475 million for this year. Analysts were guiding for $445.5 million. \n</p>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 28, 2025 15:22 ET (20:22 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IOVA","symbol_name":"Iovance Biotherapeutics, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2516306243","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2516306243","pubTimestamp":1740774120,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Iovance Biotherapeutics shares declined after its primary cancer treatment fell short of revenue expectations.The stock fell 19% to $4.28 on Friday, at one point dropping to a 52-week low of $3.62. Shares are down 75% in the past year.The San Carlos, Calif., biotechnology company said Thursday revenue from Amtagvi was $48.7 million in the fourth quarter, missing Wall Street's estimate of $54 million. Full-year revenue for the product of $103.6 million also fell short of the $109 million analyst forecast.The February 2024 launch of Amtagvi, which treats patients with metastatic melanoma, was the primary driver of revenue growth during the year, Iovance said.Revenue overall rose to $73.7 million, up from $482 million the year before. Analysts polled by FactSet expected revenue of $72.1 million.Iovance posted a loss of $78.6 million, or 26 cents a share, compared with a loss of $116.4 million, or 45 cents a share, in the prior year. Analysts expected a loss of 27 cents a share, according ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"IOVA":"Iovance Biotherapeutics, Inc."},"translate_title":"癌症药物销量未达预期后Iovance股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IOVA":0.9},"content_text":"By Katherine Hamilton \n\n\n  Iovance Biotherapeutics shares declined after its primary cancer treatment fell short of revenue expectations. \n\n\n  The stock fell 19% to $4.28 on Friday, at one point dropping to a 52-week low of $3.62. Shares are down 75% in the past year. \n\n\n  The San Carlos, Calif., biotechnology company said Thursday revenue from Amtagvi was $48.7 million in the fourth quarter, missing Wall Street's estimate of $54 million. Full-year revenue for the product of $103.6 million also fell short of the $109 million analyst forecast. \n\n\n  The February 2024 launch of Amtagvi, which treats patients with metastatic melanoma, was the primary driver of revenue growth during the year, Iovance said. \n\n\n  Revenue overall rose to $73.7 million, up from $482 million the year before. Analysts polled by FactSet expected revenue of $72.1 million. \n\n\n  Iovance posted a loss of $78.6 million, or 26 cents a share, compared with a loss of $116.4 million, or 45 cents a share, in the prior year. Analysts expected a loss of 27 cents a share, according to FactSet. \n\n\n  Iovance reaffirmed its total product revenue guidance of $450 million to $475 million for this year. Analysts were guiding for $445.5 million. \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 28, 2025 15:22 ET (20:22 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2516306243","isCrawlerRequest":true}